World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
27036
World Ranking
13674
National Ranking
1272

Overview

John B. Porter is affiliated with University College London in the United Kingdom. Their research primarily focuses on medicine, with extensive work across several specialized subfields including genetics, hematology, endocrinology, diabetes and metabolism, molecular biology, and physiology.

The scientist has contributed significantly to the study of hemoglobinopathies and related disorders. Other main research topics include blood groups and transfusion, iron metabolism and disorders, adrenal hormones and disorders, erythrocyte function and pathophysiology, sexual differentiation and disorders, and erythropoietin and anemia treatment.

Recent notable publications include:

  • A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia, 2020, New England Journal of Medicine
  • 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia, 2022, HemaSphere
  • Betibeglogene Autotemcel Gene Therapy for Non-β 00 Genotype β-Thalassemia, 2021, New England Journal of Medicine
  • Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia, 2021, The Journal of Clinical Endocrinology & Metabolism
  • Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial, 2022, The Lancet Haematology

The scientist frequently collaborates with several other researchers. Frequent co-authors include:

  • Maria Domenica Cappellini
  • Vip Viprakasit
  • Alì Taher
  • Alexis A. Thompson
  • Ashutosh Lal

Publications by the scientist are commonly found in journals that include:

  • Blood
  • HemaSphere
  • Endocrine Abstracts
  • American Journal of Hematology
  • British Journal of Haematology

Best Publications

  • Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload

    LJ Anderson;S Holden;B Davis;E Prescott

  • A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

    Maria Domenica Cappellini;Alan Cohen;Antonio Piga;Mohamed Bejaoui

  • Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major

    P. Kirk;M. Roughton;J.B. Porter;J.M. Walker

  • Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major

    Paul Kirk;Michael Roughton;John B Porter;John M Walker

  • Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)

    Maria Domenica Cappellini;Alan Cohen;John Porter;Ali Taher

  • On T2* Magnetic Resonance and Cardiac Iron

    John-Paul Carpenter;Taigang He;Paul Kirk;Michael Roughton

  • Practical management of iron overload

    John B. Porter

  • Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance.

    Lisa J. Anderson;Mark A. Westwood;Sally Holden;Bernard Davis

  • Cardiovascular Function and Treatment in β-Thalassemia Major: A Consensus Statement From the American Heart Association

    Dudley J. Pennell;James E. Udelson;Andrew E. Arai;Biykem Bozkurt

  • Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia

    Bernard A. Davis;John B. Porter

  • Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.

    Maria Domenica Cappellini;John Porter;Amal El-Beshlawy;Chi Kong Li

  • Oxidative stress and inflammation in iron-overloaded patients with β-thalassaemia or sickle cell disease

    Patrick B. Walter;Ellen B. Fung;David W. Killilea;Qing Jiang

  • A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

    Elliott Vichinsky;Onyinye Onyekwere;John Porter;Paul Swerdlow

  • Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study

    John Porter;Renzo Galanello;Giuseppe Saglio;Ellis E.J. Neufeld

  • Guidelines for the Clinical Management of Thalassaemia

    Cappellini;Cohen A;Eleftheriou A;Piga A

  • Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up

    M. Domenica Cappellini;Mohamed Bejaoui;Leyla Agaoglu;Duran Canatan

  • Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy

    JB Porter;RD Abeysinghe;L Marshall;RC Hider

  • A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia

    M Domenica Cappellini;Vip Viprakasit;Ali T Taher;Pencho Georgiev

  • Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.

    P. S. Dobbin;R. C. Hider;A. D. Hall;P. D. Taylor

  • Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin.

    Itsaraet Gosriwatana;Olivier Loreal;Shuli Lu;Pierre Brissot

Frequent Co-Authors

Maria Domenica Cappellini
Maria Domenica Cappellini University of Milan
Dudley J. Pennell
Dudley J. Pennell National Institutes of Health
Robert C. Hider
Robert C. Hider King's College London
Elliott Vichinsky
Elliott Vichinsky University of California, San Francisco
Nancy F. Olivieri
Nancy F. Olivieri University of Toronto
Ellis J. Neufeld
Ellis J. Neufeld Boston Children's Hospital
Renzo Galanello
Renzo Galanello University of Cagliari
James C. Moon
James C. Moon University College London
Suthat Fucharoen
Suthat Fucharoen Mahidol University
Andreas E. Kulozik
Andreas E. Kulozik Heidelberg University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Embarking on a career in Medicine isn’t limited to becoming a practicing physician. Today, there are diverse online study options that complement medical careers and expand professional opportunities within the healthcare sector.

Managing hospitals or clinics is a growing field, and pursuing an online healthcare administration degree can quickly open doors to leadership and management roles. For those aiming for advanced positions, exploring affordable mha online programs helps in obtaining a master’s and gaining vital skills with less student debt.

Nursing professionals looking for the highest clinical roles may consider the cheapest online dnp programs, which make it feasible for working nurses to progress toward a Doctor of Nursing Practice. Additionally, students interested in pharmacy careers can benefit from flexible online pharmacist programs, allowing them to advance or specialize without leaving their current role.

These pathways highlight how affordable, accredited online degrees make advancing your healthcare career more accessible than ever, whether your interests are clinical, administrative, or managerial.

Best Scientists Citing John B. Porter

Trending Scientists

Recently Published Articles